Get started
Author

Peng George Wang

Observed names: Peng WANG, Peng Wang, Wang, Peng
ORCID: 0009-0007-3661-6359
Observed ORCID: 0009-0007-3661-6359
OpenAlex ID: A5129567485
JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al. · Clinical Cancer Research · 16
Multiplex detection of biogenic amines with SERS sensor array boosted by (metallo)porphyrin-based hydrogen-bonded organic frameworks
2026 · Xiaolan Wei, Peng Wang, et al. · Analytical and Bioanalytical Chemistry · 1
Table S7 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Table S9 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Table S2 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Table S10 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Table S4 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Table S6 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Table S8 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Table S11 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Figure S1 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Table S12 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Table S3 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Table S5 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Table S1 from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312
2026 · Peng Wang, Xin Sun, et al.
Efficient and Interpretable Multi-Agent LLM Routing via Ant Colony Optimization
2026 · Wang, Xudong, Zhang, Chaoning, et al. · arXiv (Cornell University)
PDF
Professor WANG Peng’s medication experience in treating COPD based on the principle of “Time-specific treatment”
2026 · Zeyuan LUO, Peng WANG, et al. · Lishizhen Medicine and Materia Medica Research
PDF
Discovery of Novel Bifunctional Agents as Potent TRK Inhibitors and Degraders against xDFG Mutation Resistance
2025 · Jian Song, Jingjie Zhu, et al. · Journal of Medicinal Chemistry
Supplementary Table S2 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S4 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S7 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S9 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Data from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S6 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Supplementary Figure S1 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies
2025 · Di Kang, Yanping Wang, et al.
Works count: 53
Citation count: 17
H-index: 1
I10-index: 1
Year
Topic
Type